#NewAseBioMember | "AseBio represents the natural meeting point of the biotech ecosystem in Spain"

AseBio. What does your company's work bring to the table and what is its strength? 

Susana Castel. At Atlas Molecular Pharma, we focus on the discovery and development of innovative therapies for rare diseases, with a specialized approach based on the use of pharmacological chaperones. 

Our main strength lies in our ability to identify, through our proprietary CHASSYS platform, compounds with therapeutic potential capable of stabilizing structurally altered proteins and restoring their function. 

This approach allows us to address diseases with a high unmet medical need with exceptional molecular precision. We offer a robust translational model aimed at turning cutting-edge science into concrete therapeutic solutions, identifying and developing differentiated candidates with high potential clinical impact and efficiently accelerating their path to patients.

 AseBio. What is AseBio for you? 

Susana Castel. For us, AseBio represents the natural meeting point of the biotech ecosystem in Spain. It is an association that connects the different stakeholders and promotes the visibility and relevance of the sector, both nationally and internationally. It is a key player in the consolidation of the Spanish biotech ecosystem. 

AseBio. When did you first hear about AseBio? 

Susana Castel. I have been familiar with AseBio for many years, specifically since 2005, when the biotech sector was beginning to take shape in Spain. I have followed its evolution very closely and have been a member of the association in previous stages, so rejoining now with Atlas is a step that is well aligned with the company’s evolution and current stage. 

AseBio. What do you expect from being part of an association like AseBio? 
Susana Castel. We hope to continue contributing actively to the ecosystem, sharing experiences, and generating synergies with other players in the sector. For Atlas, being part of AseBio is also an opportunity to strengthen our visibility, gain access to strategic initiatives, and participate in dialogue with regulators and key stakeholders. In a sector such as biotech, where collaboration is essential, associations like AseBio play a fundamental role.

The biggest challenge, both for the sector and for Atlas, is successfully bridge the gap between scientific excellence and real market access. This involves not only securing solid and sustained funding during the critical stages of clinical development but also achieving greater agility in regulatory processes and in pricing and reimbursement frameworks. 

AseBio. What is the biggest challenge facing the biotech sector or your company? 
Susana Castel. In Atlas’s case, the challenge is to advance our programs while maintaining the right balance between scientific rigor, development efficiency, and value creation, particularly in rare and ultra-rare indications that currently lack therapeutic alternatives and where traditional models do not always apply.